Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update

Charles River Laboratories International, Inc. (NYSE:CRL) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 3,537,661 shares, a growth of 19.8% from the February 12th total of 2,953,939 shares. Based on an average trading volume of 1,579,421 shares, the days-to-cover ratio is currently 2.2 days. Currently, 7.3% of the shares of the stock are short sold. Currently, 7.3% of the shares of the stock are short sold. Based on an average trading volume of 1,579,421 shares, the days-to-cover ratio is currently 2.2 days.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Robert W. Baird set a $193.00 price objective on shares of Charles River Laboratories International in a research report on Thursday, February 19th. Evercore upped their price objective on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. TD Cowen lowered their target price on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Finally, Argus set a $200.00 price target on Charles River Laboratories International in a report on Monday, November 17th. Ten equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $203.57.

Hedge Funds Weigh In On Charles River Laboratories International

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tema Etfs LLC acquired a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $26,000. Neo Ivy Capital Management acquired a new position in shares of Charles River Laboratories International during the second quarter worth $29,000. Rothschild Investment LLC boosted its stake in shares of Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 84 shares during the period. Atlantic Union Bankshares Corp acquired a new stake in Charles River Laboratories International during the 3rd quarter valued at $31,000. Finally, Los Angeles Capital Management LLC purchased a new stake in Charles River Laboratories International during the 4th quarter worth $42,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 1.1%

Shares of NYSE CRL traded up $1.67 during midday trading on Tuesday, hitting $153.64. The stock had a trading volume of 755,081 shares, compared to its average volume of 1,221,420. The company has a fifty day moving average price of $189.21 and a 200 day moving average price of $180.99. The company has a market capitalization of $7.56 billion, a price-to-earnings ratio of -51.91, a PEG ratio of 2.60 and a beta of 1.64. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $228.88. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The firm had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. During the same quarter last year, the firm posted $2.66 earnings per share. Charles River Laboratories International’s revenue for the quarter was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, analysts predict that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.